Emphysema is a progressive lung disease primarily caused by prolonged exposure to harmful substances that damage the lungs. As one of the primary components of chronic obstructive pulmonary disease (COPD), emphysema is responsible for significant global health burdens. The leading causes of emphysema include smoking, long-term exposure to air pollutants, and occupational hazards.
The emphysema market is estimated to be valued at USD 5.15 Bn in 2024 and is expected to reach USD 6.7 Bn by 2031, growing at a compound annual growth rate (CAGR) of 3.8% from 2024 to 2031.
The major players operating in the Emphysema Market include Boehringer Ingelheim GmbH, AstraZeneca plc, GlaxoSmithKline plc, Novartis International AG, F. Hoffmann-La Roche Ltd, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sunovion Pharmaceuticals Inc., and Mylan N.V.
Smoking is by far the most common cause of emphysema. Cigarette smoke contains toxins that lead to inflammation in the lungs and damage the alveoli, which are the air sacs responsible for oxygen exchange. This damage reduces the lungs' ability to expel air, making it increasingly difficult for individuals with emphysema to breathe. Smokers who have smoked for many years are at the highest risk, but even people who have smoked for a shorter period can develop the disease.
Another significant contributor to emphysema is exposure to air pollution, particularly in urban areas or places with high industrial activity. Fine particulate matter and other pollutants can irritate the airways and lead to long-term damage, even in individuals who do not smoke. Occupational exposure to dust, chemicals, and fumes is also a major risk factor, particularly for workers in industries like mining, construction, and agriculture.
The impact of emphysema on healthcare systems is substantial. As the disease progresses, patients often require long-term medical care, including medications, oxygen therapy, and frequent hospitalizations. This can place a significant strain on healthcare resources, especially as the global population ages. The rising prevalence of emphysema also increases the demand for healthcare professionals who specialize in pulmonology and respiratory care.
In addition to the direct healthcare costs, emphysema also results in a significant economic burden due to lost productivity. Patients with severe emphysema often experience a reduced quality of life and may be unable to work or perform everyday tasks. The loss of productivity, along with the associated healthcare costs, makes emphysema a serious economic concern for both individuals and governments.
Preventing emphysema involves addressing the leading causes of the disease, such as reducing smoking rates, improving air quality, and protecting workers from hazardous exposures. The emphasis on prevention and early diagnosis will be essential in managing the long-term healthcare impacts of emphysema.
In conclusion, emphysema poses a significant challenge to healthcare systems worldwide. As the number of cases continues to rise, efforts to reduce risk factors, improve treatment options, and manage healthcare costs will be crucial in mitigating the impact of this debilitating disease.
Get This Report in Japanese Language: 肺気腫市場
Get This Report in Korean Language: 폐기종 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
